Passive anti-amyloid immunotherapy in Alzheimer's disease: What are the most promising targets?

Immunity and Ageing

Volumn 10, Issue 1, 2013, Pages

  Moreth, Jens ^a   Mavoungou, Chrystelle ^a   Schindowski, Katharina ^a  

^a Biberach University of Applied Science   (Germany)

Author keywords

ADDLs; Dementia; Effector function; Oligomers; Passive immunization; Protofibrils; Regulatory strategy; Therapeutic antibodies

Indexed keywords

AAB 003; ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN ANTIBODY; AMYLOID BETA PROTEIN[1-42]; APOENZYME; APOLIPOPROTEIN E4; BAN 2401; BAPINEUZUMAB; CRENEZUMAB; GANTENERUMAB; GSK 933776; IMMUNOGLOBULIN G; RO 4909832; SAR 228810; SOLANEZUMAB; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; BLOOD BRAIN BARRIER; DRUG MECHANISM; DRUG TARGETING; HUMAN; IMMUNOTHERAPY; MENINGOENCEPHALITIS; NONHUMAN; PASSIVE IMMUNIZATION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN AGGREGATION; REVIEW;

EID: 84877254025     PISSN: None     EISSN: 17424933     Source Type: Journal    
DOI: 10.1186/1742-4933-10-18     Document Type: Review

References (91)

1. World Alzheimer Report 2009, http://www.alz.co.uk/research/world-report.
2. Wyss-Coray T. Inflammation in Alzheimer disease: driving force, bystander or beneficial response?. Nat Med 2006, 12:1005-1015.
3. Selkoe DJ. Alzheimer's Disease: Genes, Proteins, and Therapy. Physiol Rev 2001, 81:741-766.
4. Atwood CS, Martins RN, Smith MA, Perry G. Senile plaque composition and posttranslational modification of amyloid-beta peptide and associated proteins. Peptides 2002, 23:1343-1350. 10.1016/S0196-9781(02)00070-0, 12128091.
5. Hardy J, Allsop D. Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol Sci 1991, 12:383-388.
6. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297:353-356. 10.1126/science.1072994, 12130773.
7. Verdile G, Fuller S, Atwood CS, Laws SM, Gandy SE, Martins RN. The role of beta amyloid in Alzheimer's disease: still a cause of everything or the only one who got caught?. Pharmacol Res 2004, 50:397-409. 10.1016/j.phrs.2003.12.028, 15304237.
8. Bitan G, Vollers SS, Teplow DB. Elucidation of primary structure elements controlling early amyloid beta-protein oligomerization. J Biol Chem 2003, 278:34882-34889. 10.1074/jbc.M300825200, 12840029.
9. Kuo YM, Emmerling MR, Vigo-Pelfrey C, Kasunic TC, Kirkpatrick JB, Murdoch GH, Ball MJ, Roher AE. Water-soluble Abeta (N-40, N-42) oligomers in normal and Alzheimer disease brains. J Biol Chem 1996, 271:4077-4081. 10.1074/jbc.271.8.4077, 8626743.
10. Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, Morgan TE, Rozovsky I, Trommer B, Viola KL, Wals P, Zhang C, Finch CE, Krafft GA, Klein WL. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA 1998, 95:6448-6453. 10.1073/pnas.95.11.6448, 27787, 9600986.
11. Kuperstein I, Broersen K, Benilova I, Rozenski J, Jonckheere W, Debulpaep M, Vandersteen A, Segers-Nolten I, Van Der Werf K, Subramaniam V, Braeken D, Callewaert G, Bartic C, D'Hooge R, Martins IC, Rousseau F, Schymkowitz J, De Strooper B. Neurotoxicity of Alzheimer's disease Abeta peptides is induced by small changes in the Abeta42 to Abeta40 ratio. EMBO J 2010, 29:3408-3420. 10.1038/emboj.2010.211, 2957213, 20818335.
12. Katzman R. Alzheimer's disease. N Engl J Med 1986, 314:964-973. 10.1056/NEJM198604103141506, 2870433.
13. Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, Hansen LA, Katzman R. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol 1991, 30:572-580. 10.1002/ana.410300410, 1789684.
14. Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, Rowan MJ, Selkoe DJ. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 2002, 416:535-539. 10.1038/416535a, 11932745.
15. Walsh DM, Selkoe DJ. A beta oligomers - a decade of discovery. J Neurochem 2007, 101:1172-1184. 10.1111/j.1471-4159.2006.04426.x, 17286590.
16. Benilova I, Karran E, De Strooper B. The toxic Abeta oligomer and Alzheimer's disease: an emperor in need of clothes. Nat Neurosci 2012, 15:349-357. 10.1038/nn.3028, 22286176.
17. O'Nuallain B, Freir DB, Nicoll AJ, Risse E, Ferguson N, Herron CE, Collinge J, Walsh DM. Amyloid beta-protein dimers rapidly form stable synaptotoxic protofibrils. J Neurosci 2010, 30:14411-14419. 10.1523/JNEUROSCI.3537-10.2010, 2987723, 20980598.
18. Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, Brett FM, Farrell MA, Rowan MJ, Lemere CA, Regan CM, Walsh DM, Sabatini BL, Selkoe DJ. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med 2008, 14:837-842. 10.1038/nm1782, 2772133, 18568035.
19. Walsh DM, Townsend M, Podlisny MB, Shankar GM, Fadeeva JV, El Agnaf O, Hartley DM, Selkoe DJ. Certain inhibitors of synthetic amyloid beta-peptide (Abeta) fibrillogenesis block oligomerization of natural Abeta and thereby rescue long-term potentiation. J Neurosci 2005, 25:2455-2462. 10.1523/JNEUROSCI.4391-04.2005, 15758153.
20. Ahmed M, Davis J, Aucoin D, Sato T, Ahuja S, Aimoto S, Elliott JI, Van Nostrand WE, Smith SO. Structural conversion of neurotoxic amyloid-beta(1-42) oligomers to fibrils. Nat Struct Mol Biol 2010, 17:561-567. 10.1038/nsmb.1799, 2922021, 20383142.
21. Lesne S, Koh MT, Kotilinek L, Kayed R, Glabe CG, Yang A, Gallagher M, Ashe KH. A specific amyloid-beta protein assembly in the brain impairs memory. Nature 2006, 440:352-357. 10.1038/nature04533, 16541076.
22. Reed MN, Hofmeister JJ, Jungbauer L, Welzel AT, Yu C, Sherman MA, Lesne S, LaDu MJ, Walsh DM, Ashe KH, Cleary JP. Cognitive effects of cell-derived and synthetically derived Abeta oligomers. Neurobiol Aging 2011, 32:1784-1794. 10.1016/j.neurobiolaging.2009.11.007, 2895944, 20031278.
23. Barghorn S, Nimmrich V, Striebinger A, Krantz C, Keller P, Janson B, Bahr M, Schmidt M, Bitner RS, Harlan J, Barlow E, Ebert U, Hillen H. Globular amyloid beta-peptide oligomer - a homogenous and stable neuropathological protein in Alzheimer's disease. J Neurochem 2005, 95:834-847. 10.1111/j.1471-4159.2005.03407.x, 16135089.
24. Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, Cotman CW, Glabe CG. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 2003, 300:486-489. 10.1126/science.1079469, 12702875.
25. Walsh DM, Hartley DM, Kusumoto Y, Fezoui Y, Condron MM, Lomakin A, Benedek GB, Selkoe DJ, Teplow DB. Amyloid beta-protein fibrillogenesis. Structure and biological activity of protofibrillar intermediates. J Biol Chem 1999, 274:25945-25952. 10.1074/jbc.274.36.25945, 10464339.
26. Hoshi M, Sato M, Matsumoto S, Noguchi A, Yasutake K, Yoshida N, Sato K. Spherical aggregates of beta-amyloid (amylospheroid) show high neurotoxicity and activate tau protein kinase I/glycogen synthase kinase-3beta. Proc Natl Acad Sci USA 2003, 100:6370-6375. 10.1073/pnas.1237107100, 164453, 12750461.
27. Kirschner DA, Abraham C, Selkoe DJ. X-ray diffraction from intraneuronal paired helical filaments and extraneuronal amyloid fibers in Alzheimer disease indicates cross-beta conformation. Proc Natl Acad Sci USA 1986, 83:503-507. 10.1073/pnas.83.2.503, 322888, 3455785.
28. Moreth J, Kroker KS, Schwanzar D, Schnack C, Von Arnim CAF, Hengerer B, Rosenbrock H, Kussmaul L. Globular and Protofibrillar Aβ Aggregates Impair Neurotransmission by Different Mechanisms. Biochemistry 2013, 52:1466-1476. 10.1021/bi3016444, 23374097.
29. Roychaudhuri R, Yang M, Hoshi MM, Teplow DB. Amyloid beta-protein assembly and Alzheimer disease. J Biol Chem 2009, 284:4749-4753.
30. Rahimi F, Shanmugam A, Bitan G. Structure-function relationships of pre-fibrillar protein assemblies in Alzheimer's disease and related disorders. Curr Alzheimer Res 2008, 5:319-341. 10.2174/156720508784533358, 2835858, 18537546.
31. Orgogozo J-M, Gilman S, Dartigues J-F, Laurent B, Puel M, Kirby LC, Jouanny P, Dubois B, Eisner L, Flitman S, Michel BF, Boada M, Frank A, Hock C. Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization. Neurology 2003, 61:46-54. 10.1212/01.WNL.0000073623.84147.A8, 12847155.
32. Holmes C, Boche D, Wilkinson D, Yadegarfar G, Hopkins V, Bayer A, Jones RW, Bullock R, Love S, Neal JW, Zotova E, Nicoll JA. Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 2008, 372:216-223. 10.1016/S0140-6736(08)61075-2, 18640458.
33. Mavoungou C, Schindowski K. Immunotherapy with anti-Amyloid-beta antibodies in Alzheimer's disease: A critical review on the molecules in the pipelines with regulatory considerations. Frontiers in Clinical Drug Research - Alzheimer Disorders 2013, Bentham Science Publishers, Ur Rahman A, in press.
34. Fu HJ, Liu B, Frost JL, Lemere CA. Amyloid-beta immunotherapy for Alzheimer's disease. CNS Neurol Disord Drug Targets 2010, 9:197-206. 10.2174/187152710791012017, 2895488, 20205640.
35. Greenberg SM, William Rebeck G, Vonsattel JPG, Gomez-Isla T, Hyman BT. Apolipoprotein E ?4 and cerebral hemorrhage associated with amyloid angiopathy. Ann Neurol 1995, 38:254-259. 10.1002/ana.410380219, 7654074.
36. Frisoni GB. ARIA from off-key operas?. Lancet Neurol 2012, 11:207-208. 10.1016/S1474-4422(12)70021-2, 22341028.
37. Schenk DB. Passive immunization treatment of Alzheimer's disease (US Patent) 2004,
38. Schenk DB, Bard F, Yednock T. Humanized and chimeric N-terminal amyloid beta-antibodies (US Patent) 2004,
39. Yang T, Hong S, O'Malley T, Sperling RA, Walsh DM, Selkoe DJ. New ELISAs with high specificity for soluble oligomers of amyloid ß-protein detect natural Aß oligomers in human brain but not CSF. Alzheimers Dement 2013, 9:99-112. 10.1016/j.jalz.2012.11.005, 23375565.
40. Johnson & Johnson Announces Discontinuation Of Phase 3 Development of Bapineuzumab Intravenous (IV) In Mild-To-Moderate Alzheimer's Disease http://www.jnj.com/connect/news/product/johnson-and-johnson-announces-discontinuation-of-phase-3-development-of-bapineuzumab-intravenous-iv-in-mild-to-moderate-alzheimers-disease.
41. Salloway S, Sperling R, Honig L, Porsteinsson A, Sabbagh M, Liu E, Yuen E, Lull J, Miloslavsky M, Reichert M, Ketter N, Grundman M, Black R, Brashear HR. A randomized, double-blind, placebo-controlled clinical trial of intravenous bapineuzumab in patients with Alzheimer's disease who are apolipoprotein E e4 non-carriers [abstract]. Eur J Neurol 2012, 19:SC312.
42. Sperling R, Salloway S, Raskind M, Ferris S, Liu E, Yuen E, Lu Y, Wang D, Nejadnik B, Guenzler V, Grundman M, Black R, Brashear HR. A randomized, double-blind, placebo-controlled clinical trial of intravenous bapineuzumab in patients with Alzheimer's disease who are apolipoprotein E e4 carriers [abstract]. Eur J Neurol 2012, 19. SC3012.
43. Sperling R, Salloway S, Brooks DJ, Tampieri D, Barakos J, Fox NC, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Lieberburg I, Arrighi HM, Morris KA, Lu Y, Liu E, Gregg KM, Brashear HR, Kinney GG, Black R, Grundman M. Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis. Lancet Neurol 2012, 11:241-249. 10.1016/S1474-4422(12)70015-7, 22305802.
44. Indipendent analysis of Solanezumab provides evidence that compound may remove Amyloid from brain in Alzheimer's Disease 2012, http://www.ctad.fr/07-download/Congres2012/PressRelease/Sola-Release_29Oct2012.pdf.
45. Alzheimer's Prevention Study in Genetically Defined High-Risk Patients Includes Roche, Lilly Drugs http://www.genomeweb.com/clinical-genomics/alzheimers-prevention-study-genetically-defined-high-risk-patients-includes-roch.
46. Farlow M, Arnold SE, Van Dyck CH, Aisen PS, Snider BJ, Porsteinsson AP, Friedrich S, Dean RA, Gonzales C, Sethuraman G. Safety and biomarker effects of solanezumab in patients with Alzheimer's disease. Alzheimers Dement 2012, 8:261-271. 10.1016/j.jalz.2011.09.224, 22672770.
47. Bohrmann B, Baumann K, Benz J, Gerber F, Huber W, Knoflach F, Messer J, Oroszlan K, Rauchenberger R, Richter WF. Gantenerumab: a novel human anti-Aß antibody demonstrates sustained cerebral amyloid-ß binding and elicits cell-mediated removal of human amyloid-ß. J Alzheimers Dis 2012, 28:49-69.
48. Ostrowitzki S. DDTL, et?al.: Mechanism of amyloid removal in patients with alzheimer disease treated with gantenerumab. Arch Neurol 2012, 69:198-207. 10.1001/archneurol.2011.1538, 21987394.
49. Alzheimer's Treatment Study Reports Three Years with No Decline in Memory and Function at AAIC 2012 2012, http://www.alz.org/aaic/releases/tues_1030amct_ivig_trial.asp.
50. Mullane K, Williams M. Alzheimer's Therapeutics: Continued clinical failures question the validity of the amyloid hypothesis-but what lies beyond?. Biochem Pharmacol 2012, 85:289-305.
51. Dodel R, Rominger A, Bartenstein P, Barkhof F, Blennow K, Förster S, Winter Y, Bach J-P, Popp J, Alferink J, Wiltfang J, Buerger K, Otto M, Antuono P, Jacoby M, Richter R, Stevens J, Melamed I, Goldstein J, Haag S, Wietek S, Farlow M, Jessen F. Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial. Lancet Neurol 2013, 12:233-243. 10.1016/S1474-4422(13)70014-0, 23375965.
52. Muhs A, Hickman DT, Pihlgren M, Chuard N, Giriens V, Meerschman C, Van Der Auwera I, Van Leuven F, Sugawara M, Weingertner MC. Liposomal vaccines with conformation-specific amyloid peptide antigens define immune response and efficacy in APP transgenic mice. Proc Natl Acad Sci 2007, 104:9810. 10.1073/pnas.0703137104, 1887581, 17517595.
53. Barcelona: Antibody to Sweep Up Aß Protofibrils in Human Brain http://www.alzforum.org/new/detail.asp?id=2757.
54. Eisai announces the start of the first clinical study of BAN2401, a novel monoclonal antibody targeting the neurotoxic protofibrils believed to cause Alzheimer's disease http://www.eisai.com/news/enews201044pdf.pdf.
55. A randomised, single-blind, placebo-controlled study to investigate the safety, tolerability, immunogenicity, pharmacokinetics and pharmacodynamics of intravenous infusion of GSK933776 in patients with Alzheimer's disease http://www.gsk-clinicalstudyregister.com/result_comp_list.jsp?phase=All&studyType=All&population=All&marketing=No&compound=GSK933776.
56. Black R, Ekman L, Lieberburg I, Grundman M, Callaway J, Gregg K, Jacobsen J, Gill D, Tchistiakova L, Widom A. Immunotherapy regimes dependent on ApoE status (US Patent) 2009,
57. Schupf N, Tang MX, Fukuyama H, Manly J, Andrews H, Mehta P, Ravetch J, Mayeux R. Peripheral Aß subspecies as risk biomarkers of Alzheimer's disease. Proc Natl Acad Sci 2008, 105:14052. 10.1073/pnas.0805902105, 2544577, 18779561.
58. Dunstan R, Bussiere T, Rhodes K, Engber T, Maier M, Weinreb P, Grimm J, Nitsch R, Arustu M, Qian F, Li M. Molecular characterization and preclinical efficacy [abstract]. Alzheimer's & dementia : the journal of the Alzheimer's Association 2011, 7:S457.
59. Neurimmune Therapeutics Announces Advancement of Alzheimer's Program into Preclinical Development http://www.neurimmune.com/index.php?section=news&cmd=details&newsid=7.
60. Holtzman DM, DeMattos R, Bales KR, Paul SM, Tsurushita N, Vasquez M. Humanized antibodies that sequester abeta peptide (US Patent) 2007,
61. Lilly Announces Detailed Results of the Phase 3 Solanezumab EXPEDITION Studies Following a Presentation of the Independent Analyses by the Alzheimer's Disease Cooperative Study (ADCS) http://newsroom.lilly.com/releasedetail.cfm?ReleaseID=702211.
62. Eli Lilly and Company Announces Top-Line Results on Solanezumab Phase 3 Clinical Trials in Patients with Alzheimer's Disease http://newsroom.lilly.com/releasedetail.cfm?ReleaseID=702211.
63. Englund H, Sehlin D, Johansson A-S, Nilsson LNG, Gellerfors P, Paulie S, Lannfelt L, Pettersson FE. Sensitive ELISA detection of amyloid-β protofibrils in biological samples. J Neurochem 2007, 103:334-345.
64. Poduslo JF, Gilles EJ, Ramakrishnan M, Howell KG, Wengenack TM, Curran GL, Kandimalla KK. HH Domain of Alzheimer's Disease Aβ Provides Structural Basis for Neuronal Binding in PC12 and Mouse Cortical/Hippocampal Neurons. PLoS One 2010, 5:e8813. 10.1371/journal.pone.0008813, 2809098, 20098681.
65. Van der Zee JS, Van Swieten P, Aalberse RC. Inhibition of complement activation by IgG4 antibodies. Clin Exp Immunol 1986, 64:415. 1542347, 3488859.
66. Bruhns P, Iannascoli B, England P, Mancardi DA, Fernandez N, Jorieux S, Daëron M. Specificity and affinity of human Fcγ receptors and their polymorphic variants for human IgG subclasses. Blood 2009, 113:3716-3725. 10.1182/blood-2008-09-179754, 19018092.
67. Adolfsson O, Pihlgren M, Toni N, Varisco Y, Buccarello AL, Antoniello K, Lohmann S, Piorkowska K, Gafner V, Atwal JK, Maloney J, Chen M, Gogineni A, Weimer RM, Mortensen DL, Friesenhahn M, Ho C, Paul R, Pfeifer A, Muhs A, Watts RJ. An Effector-Reduced Anti-β-Amyloid (Aβ) Antibody with Unique Aβ Binding Properties Promotes Neuroprotection and Glial Engulfment of Aβ. J Neurosci 2012, 32:9677-9689. 10.1523/JNEUROSCI.4742-11.2012, 22787053.
68. Ravetch J, Fukuyama H. Antibodies specific for the Protofibrilar Form of Beta-Amyloid Protein (US Patent) 2009,
69. Esslinger C, Grimm J, Hock C, Knobloch M. Nitsch R 2008, Method of Providing Disease-Specific Binding Molecules and Targets (US Patent): Tissot K.
70. Dunstan R, Bussiere T, Engber T, Weinreb P, Maier M, Grimm J, Rhodes K, Arastu M, Li M, Zhang X. The role of brain macrophages on the clearance of amyloid plaques following the treatment of Tc2576 with BIIB037 [abstract]. Alzheimer's & dementia: the journal of the Alzheimer's Association 2011, 7:S700.
71. Hillen H, Barghorn S, Striebinger A, Labkovsky B, Muller R, Nimmrich V, Nolte MW, Perez-Cruz C, Van der Auwera I, Van Leuven F, Van Gaalen M, Bespalov AY, Schoemaker H, Sullivan JP, Ebert U. Generation and therapeutic efficacy of highly oligomer-specific beta-amyloid antibodies. J Neurosci 2010, 30:10369-10379. 10.1523/JNEUROSCI.5721-09.2010, 20685980.
72. Relo A, Barghorn S, Ebert U, Hillen H, Gross G, Schoemaker H, Bespalov A. Restoration of home cage activity in Tg2576 mice by immunotherapy with the Ab-oligomer selective antibody A-887755. Alzheimer's & dementia: the journal of the Alzheimer's Association 2011, 7:S772.
73. New Drug Trial Seeks to Stop Alzheimer's Before It Starts http://www.nytimes.com/2012/05/16/health/research/prevention-is-goal-of-alzheimers-drug-trial.html.
74. Du Y, Dodel R. Human beta-amyloid antibody and use thereof for treatment of alzheimer's disease (US Patent) 2001,
75. Weksler ME, Relkin N, Turkenich R, LaRusse S, Zhou L, Szabo P. Patients with Alzheimer disease have lower levels of serum anti-amyloid peptide antibodies than healthy elderly individuals. Exp Gerontol 2002, 37:943-948. 10.1016/S0531-5565(02)00029-3, 12086704.
76. Dodel RC, Du Y, Depboylu C, Hampel H, Frolich L, Haag A, Hemmeter U, Paulsen S, Teipel SJ, Brettschneider S, Spottke A, Nolker C, Moller HJ, Wei X, Farlow M, Sommer N, Oertel WH. Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's disease. J Neurol Neurosurg Psychiatry 2004, 75:1472-1474. 10.1136/jnnp.2003.033399, 1738770, 15377700.
77. Fillit H, Hess G, Hill J, Bonnet P, Toso C. IV immunoglobulin is associated with a reduced risk of Alzheimer disease and related disorders. Neurology 2009, 73:180-185. 10.1212/WNL.0b013e3181ae7aaf, 19620605.
78. Weksler ME. The immunotherapy of Alzheimer's disease. Immun Ageing 2004, 1:2. 10.1186/1742-4933-1-2, 544955, 15679923.
79. Britschgi M, Olin CE, Johns HT, Takeda-Uchimura Y, LeMieux MC, Rufibach K, Rajadas J, Zhang H, Tomooka B, Robinson WH, Clark CM, Fagan AM, Galasko DR, Holtzman DM, Jutel M, Kaye JA, Lemere CA, Leszek J, Li G, Peskind ER, Quinn JF, Yesavage JA, Ghiso JA, Wyss-Coray T. Neuroprotective natural antibodies to assemblies of amyloidogenic peptides decrease with normal aging and advancing Alzheimer's disease. Proc Natl Acad Sci USA 2009, 106:12145-12150. 10.1073/pnas.0904866106, 2715538, 19581601.
80. Mengel D, Roskam S, Neff F, Balakrishnan K, Deuster O, Gold M, Oertel WH, Bacher M, Bach J-P, Dodel R. Naturally occurring autoantibodies interfere with [beta]-amyloid metabolism and improve cognition in a transgenic mouse model of Alzheimer/'s disease 24h after single treatment. Transl Psychiatry 2013, 3:233-243.
81. Dodel R, Balakrishnan K, Keyvani K, Deuster O, Neff F, Andrei-Selmer LC, Roskam S, Stuer C, Al-Abed Y, Noelker C, Balzer-Geldsetzer M, Oertel W, Du Y, Bacher M. Naturally occurring autoantibodies against beta-amyloid: investigating their role in transgenic animal and in vitro models of Alzheimer's disease. J Neurosci 2011, 31:5847-5854. 10.1523/JNEUROSCI.4401-10.2011, 21490226.
82. McLaurin J, Cecal R, Kierstead ME, Tian X, Phinney AL, Manea M, French JE, Lambermon MH, Darabie AA, Brown ME, Janus C, Chishti MA, Horne P, Westaway D, Fraser PE, Mount HT, Przybylski M, St George-Hyslop P. Therapeutically effective antibodies against amyloid-beta peptide target amyloid-beta residues 4-10 and inhibit cytotoxicity and fibrillogenesis. Nat Med 2002, 8:1263-1269. 10.1038/nm790, 12379850.
83. Relkin NR, Szabo P, Adamiak B, Burgut T, Monthe C, Lent RW, Younkin S, Younkin L, Schiff R, Weksler ME. 8-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease. Neurobiol Aging 2009, 30:1728-1736. 10.1016/j.neurobiolaging.2007.12.021, 18294736.
84. Rovira MB, Núñez L, Lafuente A, Hernandez I, Buendia M, Tarraga L, Roca I, Cuberas G, Torres M, Páez A. Peripheral amyloid-beta mobilization with the intravenous immunoglobulin Flebogamma DIF® in Alzheimer's disease patients. Alzheimers Dement 2011, 7:S456-S457.
85. Evans J. IVIG Reduced Brain Atrophy in Alzheimer's. Clinical Psychiatry News 2010, 38:12.
86. Comments on Paper and Primary News: Norman Relkin and Paul Szabo http://www.alzforum.org/pap/annotation.asp?powID=116328.
87. Kambhampaty A. Baxter's Gammagard unlikely to be successful in mild-to-moderate Alzheimer's 2013, Financial Times, http://www.ft.com/intl/cms/s/2/f5b1bb56-64c6-11e2-ac53-00144feab49a.html#axzz2Pd1gYpU7.
88. Siegel J. IVIG medication safety: a stepwise guide to product selection and use. Pharm Pract News 2010, 1-8.
89. Hofbauer L, Bruckschwaiger L, Butterweck HA, Teschner W. Affinity Chromatography for Purification of IgG from Human Plasma http://cdn.intechopen.com/pdfs/33051/InTech-Affinity_chromatography_for_purification_of_igg_from_human_plasma.pdf.
90. Broersen K, Rousseau F, Schymkowitz J. The culprit behind amyloid beta peptide related neurotoxicity in Alzheimer's disease: oligomer size or conformation?. Alzheimers Res Ther 2010, 2:12. 10.1186/alzrt36, 2949586, 20642866.
91. Jan A, Adolfsson O, Allaman I, Buccarello AL, Magistretti PJ, Pfeifer A, Muhs A, Lashuel HA. Abeta42 neurotoxicity is mediated by ongoing nucleated polymerization process rather than by discrete Abeta42 species. J Biol Chem 2011, 286:8585-8596. 10.1074/jbc.M110.172411, 3048741, 21156804.